N4 Pharma plc (AIM: N4P), the biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce the appointment of Dr
Avacta Group PLC (AIM:AVCT) Second dose escalation in phase 1 trial of AVA6000
Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin
Avacta Group PLC (AVCT.L) Appointment of Chief Scientific Officer
Appointment of Dr Fiona McLaughlin as Chief Scientific Officer of Avacta’s Therapeutics Division
Avacta Group PLC (AVCT.L) COVID-19 Rapid Antigen Test Manufacturing Partner
Avacta appoints BBI Solutions as manufacturing partner for the rapid SARS-CoV-2 antigen test being developed with Cytiva
TPI provides its latest research note on Avacta Group plc (AVCT.L).
Avacta has announced an extension to its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. (KSX: 069620, ‘Daewoong’). AffyXell Therapeutics, the joint venture established in South Korea by the
Avacta Group PLC (AVCT.L) Expanded Partnership with Daewoong Pharmaceutical
Expansion of Partnership with Daewoong Pharmaceutical to Include COVID-19 Neutrali s ing Affimer Therapy
Avacta Group PLC (AVCT.L) Update on COVID-19 Test Development Partnership
Update on COVID-19 Rapid Antigen Test Development Partnership with Cytiva
Avacta Group PLC (AVCT.L) Update on Affimer® Therapy for COVID-19 Infection
Infectivity assays carried out in collaboration with Glasgow University show that Affimer reagents prevent infection of human cells by a SARS-COV-2 model virus